Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSCohi-O Lenses for Ocular Sjögren's Syndrome
NCT07185139Phase 1Not yet recruiting
- Sponsor
- Guangdong ProCapZoom Biosciences Co., Ltd.
- Start
- Sep 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of methotrexate + streptozocin + hydrocortisone + vincristine in Sjögren's syndrome, sponsored by Guangdong ProCapZoom Biosciences Co., Ltd. Primary endpoint: Adverse events at Day 29. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
methotrexate + streptozocin + hydrocortisone + vincristine
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on NCT07185139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07185139.